Cullinan Therapeutics, Inc., also known as Cullinan Management, Inc. and trading under the stock symbol CGEM, is a biopharmaceutical company that focuses on developing innovative, patient-centric treatments for cancer. The company leverages a portfolio approach, creating individual companies dedicated to specific therapeutic areas, to increase speed and efficiency in drug development.
The company, established in 2018 and headquartered in Cambridge, Massachusetts, has earned notable recognition in its particularly focused approach to curating and incubating a portfolio of potential treatments, each housed within their bespoke biotech start-up. The portfolio scope includes macrophage immune checkpoint inhibitors, oncology cell therapy, non-alpha-based T cell engagers, and medicines that target stem cell factor.
Cullinan Therapeutics was founded by the global venture capital firm MPM Capital along with leading biotech executives Patrick Baeuerle, Kristoph Pylak, and Owen Hughes. Cullinan utilizes advanced technologies, including molecular genomics and proteomics, to isolate potential therapies which are then developed and commercialized by individual portfolio companies.
As part of their mission for cancer drug development, Cullinan is committed to investing in potentially transformative therapeutics from the discovery phase right through to commercialization. The idea is to focus on highly promising but still early-stage drugs, limiting the risk associated with the long and costly traditional drug development process.
Each portfolio company within Cullinan maintains a dedicated management team with deep sector expertise, leading to more robust and agile decision-making processes. This structure promotes a clearer focus on the scientific and clinical strategy and optimizes financing efficiency, which is critical in the high-risk, high-cost world of pharmaceutical research and development.
Cullinan's portfolio of companies currently comprises seven firms working on potential cancer therapies, including Cullinan Pearl, Cullinan Oncology, and Cullinan NexGem, among others. In January 2021, Cullinan completed its initial public offering (IPO) on the NASDAQ, demonstrating its belief in the value of transparency and public involvement in advancing healthcare research and treatment.
Cullinan Therapeutics represents an innovative, patient-first model in pharmaceutical research and development. Their diversified approach drives innovative product development while managing substantial risks in an inherently unpredictable sector. Through its focused, patient-centric model, Cullinan continues to help push the boundaries of cancer treatment, investing in hope against one of humanity's most devastating diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cullinan Therapeutics (Nasdaq: CGEM) has provided a corporate update and announced its financial results for the third quarter ended September 30, 2026, showcasing significant progress across its immunology and oncology pipelines. Key milestones include advancement of velinotamig into a global study for autoimmune cytopenias, initiation of a potentially registrational Phase 2 study for CLN-049 in AML, and an NDA submission for zipalertinib in EGFR ex20ins NSCLC. The company reported $313.8 million in cash and investments, projecting a runway into 2029.
Cullinan Therapeutics has received FDA and Australian regulatory clearance for a Phase 1b/2a trial of velinotamig, a T-cell engager, in adults with relapsing and refractory autoimmune immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The planned 72-participant study will assess the safety and tolerability of four subcutaneous doses over 48 weeks, with initiation estimated for late 2026 or early 2027. This clearance marks a significant step for Cullinan in developing targeted therapies for autoimmune diseases.
Cullinan Therapeutics and Taiho Oncology announced that their drug zipalertinib achieved a 30.2% intracranial response rate in a Phase 2 cancer trial. This result indicates clinically meaningful efficacy. The full MT Newswires article requires a premium subscription to read.
This article provides a price-driven insight for Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting divergent sentiment across all time horizons, suggesting choppy market conditions and elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to aid rule-based investment decisions. The analysis points to no clear price positioning signal and a lack of additional long-term support.
BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM) with a $40.00 price target. This aligns with a Strong Buy consensus among analysts, who predict a 145.70% upside for the stock. Despite reporting a GAAP net loss of $53.7 million in the last quarter, other firms like H.C. Wainwright also maintained a Buy rating, citing potential for growth.